NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
Bristol-Myers Squibb
EpicentRx, Inc.
Universitaire Ziekenhuizen KU Leuven
Celgene
SWOG Cancer Research Network
Vejle Hospital
Vanderbilt-Ingram Cancer Center